MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
S Casacuberta-Serra, Í González-Larreategui… - … and Targeted Therapy, 2024 - nature.com
RAS and MYC rank amongst the most commonly altered oncogenes in cancer, with RAS
being the most frequently mutated and MYC the most amplified. The cooperative interplay …
being the most frequently mutated and MYC the most amplified. The cooperative interplay …
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
C Zhou, C Li, L Luo, X Li, K Jia, N He, S Mao, W Wang… - Cancer Cell, 2024 - cell.com
Summary KRAS G12D is the most frequently mutated oncogenic KRAS subtype in solid
tumors and remains undruggable in clinical settings. Here, we developed a high affinity …
tumors and remains undruggable in clinical settings. Here, we developed a high affinity …
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
SA Long, AM Amparo, G Goodhart, S Ahmad… - Frontiers in …, 2024 - frontiersin.org
Despite significant advancements in the treatment of other cancers, pancreatic ductal
adenocarcinoma (PDAC) remains one of the world's deadliest cancers. More than 90% of …
adenocarcinoma (PDAC) remains one of the world's deadliest cancers. More than 90% of …
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
R Rosell, E Jantus-Lewintre, P Cao, X Cai… - Cell Communication and …, 2024 - Springer
Background KRAS-mutant non-small cell lung cancer (NSCLC) shows a relatively low
response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors …
response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors …
Resistance to KRAS inhibition in stage IV lung cancer
KB Sreter, MJ Catarata, M von Laffert, A Frille - Frontiers in Oncology, 2024 - frontiersin.org
Lung cancer remains the leading cause of cancer death globally. More than 50% of new
cases are diagnosed in an advanced or metastatic stage, thus contributing to the poor …
cases are diagnosed in an advanced or metastatic stage, thus contributing to the poor …
Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies
Cancer cells, like all other organisms, are adept at switching their phenotype to adjust to the
changes in their environment. Thus, phenotypic plasticity is a quantitative trait that confers a …
changes in their environment. Thus, phenotypic plasticity is a quantitative trait that confers a …
Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma
A Desai, AH Xiao, D Choi, MD Toruner, D Walden… - Cancers, 2024 - mdpi.com
Simple Summary Pancreatic cancer is predicted to be the second-highest cause of cancer
mortality in the US by 2040. It is driven by various mutations including KRAS, TP53, SMAD4 …
mortality in the US by 2040. It is driven by various mutations including KRAS, TP53, SMAD4 …
The integrated stress response in pancreatic development, tissue homeostasis, and cancer
G Malnassy, L Ziolkowski, KF Macleod, SA Oakes - Gastroenterology, 2024 - Elsevier
Present in all eukaryotic cells, the integrated stress response (ISR) is a highly coordinated
signaling network that controls cellular behavior, metabolism and survival in response to …
signaling network that controls cellular behavior, metabolism and survival in response to …
The Target Therapy Hyperbole:“KRAS (p. G12C)”—The Simplification of a Complex Biological Problem
M Chetta, A Basile, M Tarsitano, M Rivieccio, M Oro… - Cancers, 2024 - mdpi.com
Simple Summary KRAS mutations have critical roles in the etiology of cancers such as
NSCLC, CRC, and PDAC. However, therapeutic targeting of KRAS has proven difficult due …
NSCLC, CRC, and PDAC. However, therapeutic targeting of KRAS has proven difficult due …
Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer, Particularly Metastatic Melanoma
RW Sabnis - ACS Medicinal Chemistry Letters, 2024 - ACS Publications
Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer, Particularly Metastatic
Melanoma Page 1 Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer …
Melanoma Page 1 Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer …